Aurinia Completes Acquisition of Kezar Life Sciences; Shares to Delist from Nasdaq
summarizeSummary
Aurinia Pharmaceuticals has completed its acquisition of Kezar Life Sciences, with 80.24% of shares tendered, leading to Kezar's delisting from Nasdaq.
check_boxKey Events
-
Tender Offer Completed
Aurinia Pharma U.S., Inc. successfully completed its tender offer for Kezar Life Sciences, with 5,927,580 shares, representing approximately 80.24% of outstanding shares, validly tendered by the May 8, 2026 expiration.
-
Merger Finalized
The acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals was completed on May 11, 2026, with each untendered share converting into the offer price of $6.955 in cash plus one Contingent Value Right (CVR).
-
Delisting from Nasdaq
Kezar Life Sciences' common stock ceased trading on Nasdaq prior to the commencement of trading on May 11, 2026, and the company has initiated the process to delist and deregister its shares.
auto_awesomeAnalysis
This filing confirms the successful completion of Aurinia Pharmaceuticals' tender offer to acquire Kezar Life Sciences. With 80.24% of shares tendered, the merger was finalized, and Kezar's common stock will cease trading and be delisted from Nasdaq. This marks the definitive end of Kezar as an independent public entity, following the merger agreement announced on March 30, 2026, and the tender offer commencement on April 13, 2026.
At the time of this filing, KZR was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.9M. The 52-week trading range was $3.53 to $7.55. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.